Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (4527)	4/1/1998 5:11:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 9719

biowa, re: "maybe that's what big Pharma should become..." That's what many are now. They have great resources and have made a living out of buying good technology and leveraging their manufacturing, marketing and sales strengths. Look at Glaxo. Even Amgen is out buying technologies from small companies. Biogen is doing the same thing less agressively. The bigger the company, the greater the bureaucratic strengths and the less potent (per dollar capitalization) the internal R&D (at least vis-a-vis successful small biotechs). When Biogen and Genzyme and Amgen are $40B companies, they will find the path of least resistance is gobble-and-grow just as Glaxo, Merck, PNU, Eli Lilly, J&J, etc., have found.